Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate
作者: Christian BrandAhmad SadiqueJacob L. HoughtonKishore GangangariJose F. PonteJason S. LewisNaga Vara Kishore PillarsettyJason A. KonnerThomas Reiner
作者单位: 1Department of Radiology, Memorial Sloan Kettering Cancer Center
2Department of Chemistry, Hunter College and PhD Program in Chemistry, The Graduate Center of the City University of New York
3ImmunoGen, Inc
4Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center
5Department of Radiology, Weill Cornell Medical College
6Department of Medicine, Memorial Sloan Kettering Cancer Center
刊名: EJNMMI Research, 2018, Vol.8 (1), pp.1-10
来源数据库: Springer Journal
DOI: 10.1186/s13550-018-0437-x
关键词: 89 ZrCompanion diagnosticPET imagingAntibody-drug-conjugate
英文摘要: Abstract(#br) Background(#br)The folate receptor α (FRα)-targeting antibody-drug conjugate (ADC), IMGN853, shows great antitumor activity against FRα-expressing tumors in vivo, but patient selection and consequently therapy outcome are based on immunohistochemistry. The aim of this study is to develop an antibody-derived immuno-PET imaging agent strategy for targeting FRα in ovarian cancer as a predictor of treatment success.(#br) Methods(#br)We developed [ 89 Zr]Zr-DFO-M9346A, a humanized antibody-based radiotracer targeting tumor-associated FRα in the preclinical setting. [ 89 Zr]Zr-DFO-M9346A’s binding ability was tested in an in vitro uptake assay using cell lines with varying FRα expression levels. The diagnostic potential of [ 89 Zr]Zr-M9346A was evaluated in KB and OV90...
全文获取路径: Springer  (合作)
分享到:
来源刊物:

×